Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06747624 · ClinicalTrials.gov registry record · NA
A Crossover Clinical Trial Investigating the Effects of Geranylgeraniol (GG) Supplementation on Testosterone Levels in Healthy Men and Women Over an 18-week Period
A NA study of Health and Wellness, sponsored by Designs for Health.
- Active
- Registry status
- NA
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT06747624: Active NA study of Health and Wellness, sponsored by Designs for Health.
NCT06747624 is a NA study of Health and Wellness that is active but no longer recruiting, run by Designs for Health. The registered enrollment target is 40 participants, below the 3,281-participant average among 6 other Health trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06747624, a NA study of Health and Wellness, is active but no longer recruiting, sponsored by Designs for Health.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary purpose of this study is to investigate the effects of geranylgeraniol (GG) supplementation on testosterone levels in middle-aged (40 to 65 years) healthy men and women. The research team hypothesizes that geranylgeraniol (GG) supplementation will enhance testosterone levels and improve self-reported health outcomes in a healthy population.
Primary Outcome
Can aid in the diagnosis of androgen dysfunction in men and women and is more specific method of measuring testosterone concentrations. Units in ng/ml.
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT Geranylgeraniol 300 mg
Study Locations (1)
Florida
- Designs for Health, Inc. - Palm Coast
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2025-01-30 |
| Est. Completion | 2025-10 |
| Phase | NA |
What the registry record for NCT06747624 still lists
NCT06747624 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 3,281-participant average among 6 other Health trials with a reported enrollment target (99% lower).
The record links to 2 conditions, with Health appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06747624 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT06747624 about?
NCT06747624 is a clinical study titled "A Crossover Clinical Trial Investigating the Effects of Geranylgeraniol (GG) Supplementation on Testosterone Levels in Healthy Men and Women Over an 18-week Period". The primary purpose of this study is to investigate the effects of geranylgeraniol (GG) supplementation on testosterone levels in middle-aged (40 to 65 years) healthy men and women. The research team hypothesizes that geranylgeraniol (GG) supplementation will enhance testosterone levels and improve...
What is the current status of trial NCT06747624?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 40 participants. The study started on 2025-01-30. Estimated completion is 2025-10.
What conditions does trial NCT06747624 study?
This clinical trial studies the following conditions: Health, Wellness.
What interventions are being tested in trial NCT06747624?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Geranylgeraniol 300 mg (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT06747624?
This trial is sponsored by Designs for Health, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06747624 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Health
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
National Sponsorship Program for Transitioning Service Members
RECRUITING · NA
-
Nutrition for Precision Health, Powered by the All of Us
RECRUITING · NA
-
How a Single Workout Affects Gut Bugs in Women With Different Fitness Levels and Body Types
RECRUITING · NA
-
Expanding Veteran Sponsorship Initiative+ to Support High-Risk Transitioning Servicemembers and Veterans: A Precision Medicine Approach
RECRUITING · NA
-
Basic Income Guaranteed: Los Angeles Economic Assistance Pilot
COMPLETED · NA
-
Temporal Investigation of Multimodal Elements
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI